title: Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions.
abstract: We have characterized the heterogeneity of human blood NK cell subsets defined by expression of KIR, lectin like receptors and NK cell differentiation markers within a cohort of 51 healthy Caucasian individuals. High inter-individual variability in cell surface expression of most NK cell markers is observed. Range values defining NK cell subsets in healthy donors were further used as references to characterize 14 patients with NK-type lymphoproliferative disease of granular lymphocytes (NK-LDGL). Alterations of the KIR repertoire were noted in all NK-LDGL patients. NK cell expansions were classified as oligoclonal KIR(+) or as non-detectable KIR ((nd)KIR) using anti-KIR2DL1/2DS1, anti-KIR2DL2/2DL3/2DS2, anti-KIR3DL1 and anti-KIR2DS4 monoclonal antibodies. A major reduction in the size of the CD56(bright) NK cell subset was a constant feature of NK-LDGL. Altered distribution of CD94(+), CD161(+), and CD162R(+) NK cell subsets was also observed in NK-LDGL patients. Considering the potential role of NK cells in eliminating tumors or virus-infected cells, the reference values defined in this study should be valuable to characterize both quantitative and qualitative alterations of the NK cell repertoire in pathological conditions and to monitor NK cell reconstitution following hematopoietic transplantation.
authors.affiliation: Centre d'Immunologie Marseille-Luminy, INSERM-CNRS-Université Méditerranée, Marseille, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Pascal
authors.forename: Nicolas
authors.initials: N
authors.lastname: Schleinitz
authors.forename: Corinne
authors.initials: C
authors.lastname: Brunet
authors.forename: Sophie
authors.initials: S
authors.lastname: Ravet
authors.forename: Elodie
authors.initials: E
authors.lastname: Bonnet
authors.forename: Xavier
authors.initials: X
authors.lastname: Lafarge
authors.forename: Mhammed
authors.initials: M
authors.lastname: Touinssi
authors.forename: Denis
authors.initials: D
authors.lastname: Reviron
authors.forename: Jean Francois
authors.initials: JF
authors.lastname: Viallard
authors.forename: Jean Francois
authors.initials: JF
authors.lastname: Moreau
authors.forename: Julie
authors.initials: J
authors.lastname: Déchanet-Merville
authors.forename: Patrick
authors.initials: P
authors.lastname: Blanco
authors.forename: Jean Robert
authors.initials: JR
authors.lastname: Harlé
authors.forename: José
authors.initials: J
authors.lastname: Sampol
authors.forename: Eric
authors.initials: E
authors.lastname: Vivier
authors.forename: Françoise
authors.initials: F
authors.lastname: Dignat-George
authors.forename: Pascale
authors.initials: P
authors.lastname: Paul
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis*; D001782:Blood Donors; D005260:Female; D005434:Flow Cytometry; D005838:Genotype; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism*; D016131:Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism*; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011971:Receptors, Immunologic / Q000378:metabolism*; D054340:Receptors, KIR; D054342:Receptors, KIR2DL1; D054343:Receptors, KIR2DL2; D054344:Receptors, KIR2DL3; D054341:Receptors, KIR3DL1; D012016:Reference Values
chemical_list: D015415:Biomarkers; C515077:KIR2DL2 protein, human; C515083:KIR3DL1 protein, human; D011971:Receptors, Immunologic; D054340:Receptors, KIR; D054342:Receptors, KIR2DL1; D054343:Receptors, KIR2DL2; D054344:Receptors, KIR2DL3; D054341:Receptors, KIR3DL1